CapWealth Advisors LLC lifted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 185,638 shares of the biopharmaceutical company’s stock after purchasing an additional 4,241 shares during the period. Bristol-Myers Squibb makes up about 1.8% of CapWealth Advisors LLC’s holdings, making the stock its 18th biggest position. CapWealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $10,273,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in BMY. Family Management Corp grew its holdings in shares of Bristol-Myers Squibb by 8.8% during the second quarter. Family Management Corp now owns 19,805 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 1,600 shares in the last quarter. Griffin Asset Management Inc. grew its holdings in shares of Bristol-Myers Squibb by 4.0% during the second quarter. Griffin Asset Management Inc. now owns 194,501 shares of the biopharmaceutical company’s stock valued at $10,764,000 after buying an additional 7,494 shares in the last quarter. Highlander Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 23.7% during the second quarter. Highlander Capital Management LLC now owns 27,124 shares of the biopharmaceutical company’s stock valued at $1,501,000 after buying an additional 5,200 shares in the last quarter. Mutual Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 5.2% during the second quarter. Mutual Advisors LLC now owns 22,546 shares of the biopharmaceutical company’s stock valued at $1,248,000 after buying an additional 1,114 shares in the last quarter. Finally, Bridges Investment Management Inc. grew its holdings in shares of Bristol-Myers Squibb by 5.9% during the second quarter. Bridges Investment Management Inc. now owns 41,524 shares of the biopharmaceutical company’s stock valued at $2,298,000 after buying an additional 2,315 shares in the last quarter. 72.29% of the stock is currently owned by institutional investors.

A number of research analysts have recently weighed in on BMY shares. SunTrust Banks reiterated a “buy” rating and set a $67.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, July 31st. BMO Capital Markets reiterated a “hold” rating on shares of Bristol-Myers Squibb in a report on Sunday, July 22nd. Jefferies Financial Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, July 15th. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Finally, Credit Suisse Group reiterated a “hold” rating and set a $61.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $62.89.

Shares of NYSE BMY opened at $60.69 on Friday. The company has a current ratio of 1.40, a quick ratio of 1.28 and a debt-to-equity ratio of 0.46. Bristol-Myers Squibb Co has a one year low of $49.96 and a one year high of $70.05. The stock has a market capitalization of $98.61 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 1.52 and a beta of 1.02.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The firm had revenue of $5.70 billion for the quarter, compared to the consensus estimate of $5.48 billion. During the same quarter in the previous year, the company posted $0.74 earnings per share. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. equities research analysts anticipate that Bristol-Myers Squibb Co will post 3.62 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Friday, October 5th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.64%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 53.16%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.